Galectin Therapeutics/GALT

$3.97

-4.28%
-
1D1W1MYTD1YMAX

About Galectin Therapeutics

Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

Ticker

GALT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joel Lewis

Employees

14

Headquarters

Norcross, United States

GALT Metrics

BasicAdvanced
$236.47M
Market cap
-
P/E ratio
-$0.75
EPS
0.77
Beta
-
Dividend rate
$236.47M
0.77437
$4.10
$1.28
115.07K
1.768
-12.72%
-165.97%
-394.92%
-13.92%

What the Analysts think about GALT

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
177.08% upside
High $11.00
Low $11.00
$3.97
Current price
$11.00
Average price target

GALT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-9.9M
-4.81%
Profit margin
0%
-

GALT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.19
-$0.15
-$0.24
-$0.16
-
Expected
-$0.21
-$0.21
-$0.16
-$0.16
-$0.16
Surprise
-9.52%
-28.57%
50%
0%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Galectin Therapeutics stock?

Galectin Therapeutics (GALT) has a market cap of $236.47M as of April 13, 2024.

What is the P/E ratio for Galectin Therapeutics stock?

The price to earnings (P/E) ratio for Galectin Therapeutics (GALT) stock is 0 as of April 13, 2024.

Does Galectin Therapeutics stock pay dividends?

No, Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Galectin Therapeutics dividend payment date?

Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders.

What is the beta indicator for Galectin Therapeutics?

Galectin Therapeutics (GALT) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Galectin Therapeutics stock price target?

The target price for Galectin Therapeutics (GALT) stock is $11, which is 177.08% above the current price of $3.97. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Galectin Therapeutics stock

Buy or sell Galectin Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing